Get the latest tech news
OTC nasal spray reduces the risk of COVID-19 infection by 70% | Azelastine nasal spray could provide an additional easily accessible prophylactic to complement existing protective measures.
The active ingredient in a common over-the-counter allergy spray may do more than ease hay fever symptoms. A new clinical trial found azelastine cut COVID-19 infections by 70%, hinting at a cheap, accessible way to add protection alongside vaccines.
“This clinical trial is the first to demonstrate a protective effect in a real-world setting,” said Professor Robert Bals, MD, Director of Saarland’s department of Pulmonology, Allergology, Respiratory Intensive Care and Environmental Medicine. “Azelastine nasal spray could provide an additional easily accessible prophylactic to complement existing protective measures, especially for vulnerable groups, during periods of high infection rates, or before traveling.” “Our results highlight the need for larger, multicenter trials to continue exploring the use of azelastine nasal sprays as an on-demand preventive treatment, and to examine its potential effectiveness against other respiratory pathogens,” Bals said.
Or read this on r/tech
